NVCT coverage

Nuvectis just did the rare biotech dilution that actually strengthens the bull case

Nuvectis took a painful dilution hit, but this is one of the rare biotech raises that actually improves the story. A $100 million financing landed right after a pipeline expansion deal, turning NVCT from a cash-tight single-asset bet into a funded three-program clinical setup.